NCT03721835

Brief Summary

The purpose of this study is to assess the reoperation rate of fractures that have occurred at the neck of the femur that are treated with the CONQUEST FN Femoral Neck Fracture System. The CONQUEST FN Femoral Neck Fracture System is approved for use by the United States Food and Drug Administration (FDA). It consists of a stainless steel plate and up to three (3) screws intended to treat both non-displaced and displaced fractures to the femoral neck.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2018

Geographic Reach
1 country

4 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2018

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 19, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 26, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 11, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 11, 2020

Completed
3.6 years until next milestone

Results Posted

Study results publicly available

September 25, 2023

Completed
Last Updated

September 25, 2023

Status Verified

February 1, 2021

Enrollment Period

1.4 years

First QC Date

October 19, 2018

Results QC Date

February 16, 2021

Last Update Submit

September 22, 2023

Conditions

Keywords

Femoral Neck FractureHipBroken hipCONQUEST FNHip Fracture

Outcome Measures

Primary Outcomes (1)

  • Reoperation Rate at One Year Post-operation

    Reoperation for any reason from time of implantation to one-year post operation

    1 year

Secondary Outcomes (8)

  • Number of Participants With Intraoperative Complications

    7 days

  • Classification of Quality of Fracture Reduction

    Operative, 6 weeks, 3 months, 6 months, and 1 year

  • Visual Analogue Scale (VAS) for Pain

    Pre-Operative, 6 Weeks, 3 Months, 6 Months, and 1 year

  • Quality of Life - EQ-5D-5L

    Pre-Operative, 6 Weeks, 3 Months, 6 Months, and 1 year

  • Timed Up and Go (TUG)

    6 Weeks, 3 Months, 6 Months, and 1 year

  • +3 more secondary outcomes

Study Arms (1)

Control femoral neck fracture system

OTHER

This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture

Device: CONQUEST FN Femoral Neck Fracture System

Interventions

Fracture fixation device consisting of a single plate and three screws

Control femoral neck fracture system

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must be 18 years of age or older
  • Must provide written informed consent
  • Willing to make all required study visits for one year post-operation
  • Subject has experienced a displaced or non-displaced intracapsular femoral neck fracture and is scheduled for repair using the CONQUEST FN Femoral Neck Fracture System.

You may not qualify if:

  • Subject with known sensitivity or allergies to stainless steel
  • Subject with fracture occurring more than 7 days prior to surgery
  • Subject has more than one fracture on the hip requiring surgery
  • Subject is considered obese by a Body Mass Index \> 40 at the time of surgery
  • Therapy with another investigational agent within thirty 30 days of screening
  • Subject has emotional or neurological condition that precludes cooperation and compliance
  • Subject has undergone previous surgery on hip.
  • Subject has severe bow of the target hip or gross distortion of the femur.
  • Current systemic therapy with cytotoxic drugs
  • Subject has a physical condition that would preclude adequate implant support or impede healing (e.g. blood supply impairment, insufficient bone quality or quantity, or an active local or systemic infection).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Orthopaedic Trauma Institute Navicent Health Medical Center

Macon, Georgia, 31201, United States

Location

Wake Forest School of Medicine

Winston-Salem, North Carolina, 27157, United States

Location

John Peter Smith Hospital

Fort Worth, Texas, 76104, United States

Location

UT Health Science Center San Antonio

San Antonio, Texas, 78829, United States

Location

MeSH Terms

Conditions

Femoral Neck FracturesHip Fractures

Condition Hierarchy (Ancestors)

Femoral FracturesFractures, BoneWounds and InjuriesHip InjuriesLeg Injuries

Results Point of Contact

Title
Karlie Morgan
Organization
Smith+Nephew, Inc.

Study Officials

  • Karlie Morgan

    Smith & Nephew, Inc.

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 19, 2018

First Posted

October 26, 2018

Study Start

September 10, 2018

Primary Completion

February 11, 2020

Study Completion

February 11, 2020

Last Updated

September 25, 2023

Results First Posted

September 25, 2023

Record last verified: 2021-02

Locations